The Discounted Cash Flow (DCF) valuation of Intra-Cellular Therapies Inc (ITCI) is (456.50) USD. With the latest stock price at 131.87 USD, the upside of Intra-Cellular Therapies Inc based on DCF is -446.2%.
Based on the latest price of 131.87 USD and our DCF valuation, Intra-Cellular Therapies Inc (ITCI) is a sell. selling ITCI stocks now will result in a potential gain of 446.2%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.9% - 7.6% | 6.3% |
| Long-term Growth Rate | 3.0% - 4.7% | 3.8% |
| Fair Price | (4,488.99) - (239.46) | (456.50) |
| Upside | -3504.1% - -281.6% | -446.2% |